TL1A Antibody CDR Composition for High-Specificity Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Constructing effective antibodies targeting TL1A for treating inflammation-related diseases remains a significant challenge.
Innovation Solution
Development of isolated antigen-binding proteins with specific heavy and light chain variable regions, comprising defined complementarity-determining regions (CDRs) that can bind to TNF-like protein A (TL1A) with high affinity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody construction methods are used to target TL1A, then the development process becomes lengthy and complex, but the effectiveness and specificity of the antibodies remain insufficient
Solution Approach 1:
The antibody construction is divided into modular components: variable regions (VH and VL) with defined CDR sequences, constant regions, and optional Fc portions. This segmentation allows systematic assembly of functional units with predictable properties, reducing construction complexity while maintaining effectiveness.
Solution Approach 2:
The patent specifies precise amino acid sequences for CDR regions (HCDR1-3 and LCDR1-3) to optimize binding affinity and specificity to TL1A. By controlling critical parameters like CDR sequence composition and length, the antibody achieves high reliability without requiring complex iterative optimization processes.
2Measurement precision
If antibody construction focuses on high specificity to TL1A, then the development time and complexity increase significantly
Solution Approach 1:
The patent provides pre-determined CDR sequences that have been optimized for TL1A binding specificity. By performing the sequence optimization work in advance and codifying the optimal CDR patterns, the patent eliminates time-consuming iterative screening during antibody construction while maintaining high binding specificity.
Solution Approach 2:
The patent establishes a proven CDR sequence template that can be copied and adapted for TL1A-targeting antibodies. Once the optimal CDR sequences are identified, they can be replicated across multiple antibody constructs with consistent high specificity, dramatically reducing development time for subsequent antibody variants.
Data Source
AI summary
The present disclosure provides an isolated antigen-binding protein specifically binding to TNF-like protein A (TL1A), comprising a heavy chain variable region (VH) comprising at least one heavy chain complementarity-determining region (HCDR) comprising an amino acid sequence shown in SEQ ID NO:1, SEQ ID NO:5, or SEQ ID NO:14.